Response Versus Remission in Obsessive-Compulsive Disorder
The DOI matches its Crossref record.
Abstract
Article Abstract Objective: To investigate rates of response and remission in adults with obsessive-compulsive disorder (OCD) after 12 weeks of evidence-based treatment. Method: Post hoc analyses of response and remission were conducted using data from a multisite, randomized, controlled trial comparing the effects of 12 weeks of exposure and ritual prevention (EX/RP), clomipramine (CMI), their combination (EX/RP+CMI), or pill placebo (PBO) in 122 adults with OCD (DSM-III-R or DSM-IV criteria). Response was defined as a decrease in symptoms; remission was defined as minimal symptoms after treatment. Different response and remission definitions were constructed based on criteria used in prior studies. For each definition, the proportion of responders or remitters in each treatment group was then compared. Results: There were significant differences (p < .05) among the 4 treatment groups in the proportion of responders and remitters. In pairwise comparisons, EX/RP + CMI and EX/RP each produced significantly more responders and remitters than PBO; CMI produced significantly more responders and remitters than PBO for some definitions but not for others. When remission was defined as a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of 12 or less, significantly more EX/RP + CMI (18/31 ) and EX/RP (15/29 ) patients entering treatment achieved remission than either CMI (9/36 ) or PBO (0/26 ) patients. However, even in treatment completers, many CMI and some EX/RP + CMI and EX/RP patients did not achieve remission (remission rates for YBOCS < = 12: EX/RP + CMI = 13/19 ; EX/RP = 15/21 ; CMI = 8/27 ; PBO = 0/20 ). Conclusion: EX/RP (with or without CMI) can lead to superior treatment outcome compared with CMI alone in OCD patients without comorbid depression. However, many OCD patients who receive evidence-based treatment do not achieve remission.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“exposure and response prevention (ERP), which is now considered to be the first-line psychotherapy for the disorder.”
From Exposure and response prevention for obsessive-compulsive disorder: A review and new directions (2019) · cites this paper as [26]
In the citing paper
“only about half of the patients who receive it will reach complete symptom remission.[26]”
From Exposure and response prevention for obsessive-compulsive disorder: A review and new directions (2019) · cites this paper as [26]
In the citing paper
“EX/RP typically helps up to half of patients achieve minimal symptoms after treatment (i.e., remission) (12).”
From Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder (2019) · cites this paper as [12]
In the citing paper
“this cutoff not only reflects minimal symptoms after treatment but also predicts good quality of life and adaptive functioning (12,26,30).”
From Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder (2019) · cites this paper as [12]
In the citing paper
“operationalized as a posttreatment Y-BOCS score ≤ 12, given that this cutoff reflects symptom reduction and predicts good quality of life and adaptive functioning (12,26,30).”
From Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder (2019) · cites this paper as [12]
Citations
Cited by
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
“Differing definitions of response and remission applied to the data post hoc changed the magnitude but not the significance of these differences in outcome (Simpson et al. 2006).”
BackgroundSelf-citationÖst, L.-G., Havnen, A., Hansen, B., & Kvale, G. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.06.003 · Cited by 655
Mataix‐Cols, D., de la Cruz, L. F., Nordsletten, A. E., Lenhard, F., Isomura, K., & Simpson, H. B. (2016) · World Psychiatry · doi:10.1002/wps.20299 · Cited by 386
Self-citationShould an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?
Phillips, K. A., Stein, D. J., Rauch, S. L., Hollander, E., Fallon, B. A., Barsky, A., Fineberg, N., Mataix-Cols, D., Ferrão, Y. A., Saxena, S., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20705 · Cited by 347
“The response rate to placebo in OCD using the same scale can be much lower, closer to 10%,([309,310]) suggesting that the pathophysiologic mechanisms that perpetuate each of these disorders may differ.”
BackgroundEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Simpson, H. B., Foa, E. B., Liebowitz, M. R., Ledley, D. R., Huppert, J. D., Cahill, S., Vermes, D., Schmidt, A. B., Hembree, E., Franklin, M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07091440 · Cited by 316
Self-citationSTORCH, E. A., MERLO, L. J., LARSON, M. J., GEFFKEN, G. R., LEHMKUHL, H. D., JACOB, M. L., MURPHY, T. K., & GOODMAN, W. K. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31816774b1 · Cited by 291
Efficacy of cognitive-behavioral therapy for obsessive-compulsive disorder
McKay, D., Sookman, D., Neziroglu, F., Wilhelm, S., Stein, D. J., Kyrios, M., Matthews, K., & Veale, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.058 · Cited by 283
“Simpson et al., 2006 reported that 37% (7 out of 19) of patients who received three months of cognitive behavior therapy (CBT) plus Anafranil had recovered.”
BackgroundResultMantovani, A., Simpson, H. B., Fallon, B. A., Rossi, S., & Lisanby, S. H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990435 · Cited by 281
“Up to 40–60% of obsessive–compulsive disorder (OCD) patients do not have a satisfactory outcome with currently available treatments (Pallanti et al. 2002 ; Simpson et al. 2006).”
BackgroundSelf-citationAndersson, E., Enander, J., Andrén, P., Hedman, E., Ljótsson, B., Hursti, T., Bergström, J., Kaldo, V., Lindefors, N., Andersson, G., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291712000244 · Cited by 274
“Cognitive behaviour therapy (CBT) is considered to be an evidence-based treatment for OCD, with response rates averaging 50–70% (Abramowitz, 2006 ; Simpson et al. 2006).”
Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder
Goodman, W. K., Storch, E. A., & Sheth, S. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111601 · Cited by 250
Simpson, H. B., Foa, E. B., Liebowitz, M. R., Huppert, J. D., Cahill, S., Maher, M. J., McLean, C. P., Bender, J., Marcus, S. M., Williams, M. T., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1932 · Cited by 248
“Forexample, McDougle et al6 treated patients for 8 weeks with an SRI and then randomized only those who met all of the following criteria: (1) less than 35% Y-BOCS score decrease or Y-BOCS score more than 16; (2) no more than minimal improvement; and (3) consensus of 3 clinicians that the patient was unimproved.”
Self-citationTreatment Response, Symptom Remission, and Wellness in Obsessive-Compulsive Disorder
Farris, S. G., McLean, C. P., Van Meter, P. E., Simpson, H. B., & Foa, E. B. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07789 · Cited by 216
Self-citationSimpson, H. B., Maher, M. J., Wang, Y., Bao, Y., Foa, E. B., & Franklin, M. (2011) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0022659 · Cited by 217
Self-citationBerlim, M. T., Neufeld, N. H., & Van den Eynde, F. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.022 · Cited by 219
“However, even with such diverse therapeutic options, up to 60% of patients with OCD are either unable to tolerate medication side-effects or only partially improve following treatment, and are thereby left with persistent symptoms with lasting repercussions on their global functioning and well-being (Jenike, 2004; Pal…”
BackgroundEmpirically Supported Treatment: Recommendations for a New Model
Tolin, D. F., McKay, D., Forman, E. M., Klonsky, E. D., & Thombs, B. D. (2015) · Clinical Psychology: Science and Practice · doi:10.1111/cpsp.12122 · Cited by 219
“…SCIENCE AND PRACTICE V22 N4, DECEMBER 2015 response and remission (Andreasen et al., 2005; Doyle & Pollack, 2003; Frank et al., 1991; McIntyre, Fallu, & Konarski, 2006; Simpson, Huppert, Petkova, Foa, & Liebowitz, 2006), usually operationalized as a cutoff score on a standardized measure.”
BackgroundRussell, A. J., Jassi, A., Fullana, M. A., Mack, H., Johnston, K., Heyman, I., Murphy, D. G., & Mataix-Cols, D. (2013) · Depression and Anxiety · doi:10.1002/da.22053 · Cited by 160
“[28] A YBOCS total score of ≤12 for 1 week or more was used to define remission[28] with remission lasting for longer than 1 month”
MethodStorch, E. A., Lewin, A. B., De Nadai, A. S., & Murphy, T. K. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.04.005 · Cited by 158
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
“…of ‘relapse’ continue to spark debate and can be difficult to apply to an illness that usually has a chronic fluctuating course or a progressively worsening course when untreated, and shows only partial response to long-term pharmacological treatment (Simpson et al., 2006; Farris et al., 2013).”
BackgroundSelf-citationBrain Stimulation in Obsessive-Compulsive Disorder (OCD): A Systematic Review
Rapinesi, C., Kotzalidis, G. D., Ferracuti, S., Sani, G., Girardi, P., & Del Casale, A. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190409142555 · Cited by 143
Exposure and response prevention for obsessive-compulsive disorder: A review and new directions
Simpson, H., & Hezel, D. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_516_18 · Cited by 161
“Although the current guidelines recommend ERP as the first-line treatment for OCD, only about half of the patients who receive it will reach complete symptom remission.[26] There are a number of factors that are associated with poor response, including lack of adherence to treatment, poor insight, comorbid depression,…”
BackgroundSelf-citationMantione, M., Nieman, D. H., Figee, M., & Denys, D. (2014) · Psychological Medicine · doi:10.1017/s0033291714000956 · Cited by 129
“Patients usually have only a partial response to medication (Eddy et al. 2004) and CBT (Simpson et al. 2006, 2008).”
BackgroundGomes, P. V. O., Brasil-Neto, J. P., Allam, N., & Rodrigues de Souza, E. (2012) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.11100242 · Cited by 126
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Romanelli, R. J., Wu, F. M., Gamba, R., Mojtabai, R., & Segal, J. B. (2014) · Depression and Anxiety · doi:10.1002/da.22232 · Cited by 121
“The risk of bias in each study was assessed using a tool from the Cochrane Collaboration for RCTs.[17] High or low risk of bias Depression and Anxiety was assigned in the following categories: adequate allocation sequence, allocation concealment, masking of evaluators, and methods for dealing with incomplete data outc…”
BackgroundInfluentialAndersson, E., Hedman, E., Enander, J., Radu Djurfeldt, D., Ljótsson, B., Cervenka, S., Isung, J., Svanborg, C., Mataix-Cols, D., Kaldo, V., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0546 · Cited by 109
D'Urso, G., Brunoni, A. R., Mazzaferro, M. P., Anastasia, A., de Bartolomeis, A., & Mantovani, A. (2016) · Depression and Anxiety · doi:10.1002/da.22578 · Cited by 107
The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence
Schön, M., Mousa, A., Berk, M., Chia, W. L., Ukropec, J., Majid, A., Ukropcová, B., & de Courten, B. V. (2019) · Nutrients · doi:10.3390/nu11061196 · Cited by 114
Mindfulness-based cognitive therapy as an augmentation treatment for obsessive-compulsive disorder.
Key, B. L., Rowa, K., Bieling, P., McCabe, R., & Pawluk, E. J. (2017) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2076 · Cited by 103
Hertenstein, E., Rose, N., Voderholzer, U., Heidenreich, T., Nissen, C., Thiel, N., Herbst, N., & Külz, A. K. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-185 · Cited by 102
“However, in a recent investigation of an extensive therapy program including daily therapist-assisted exposure and response prevention exercises over a period of three weeks, only 55% of the patients could be classified as treatment responders when response was defined as a decrease of symptom severity by at least 35%…”
BackgroundSimpson, H. B., Zuckoff, A. M., Maher, M. J., Page, J. R., Franklin, M. E., Foa, E. B., Schmidt, A. B., & Wang, Y. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.05.026 · Cited by 100
Self-citationLewin, A. B., & Piacentini, J. C. (2010) · Child & Youth Care Forum · doi:10.1007/s10566-009-9092-8 · Cited by 105
“Cut-off scores have varied in the child OCD literature; based on guidelines proposed by Frank et al. 1991, Simpson et al. (2006) proposed that remission for adult-OCD be considered a Y-BOCS1 score of B12 for at least 1 week.”
BackgroundMethodTolin, D. F., Diefenbach, G. J., & Gilliam, C. M. (2011) · Depression and Anxiety · doi:10.1002/da.20804 · Cited by 98
“This score is comparable to other definitions of clinical remission[50] and these responder criteria were validated in our pilot studies.”
ResultMantovani, A., Rossi, S., Bassi, B. D., Simpson, H. B., Fallon, B. A., & Lisanby, S. H. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.08.054 · Cited by 98
“After 4 weeks of treatment, clinical response rate, defined as Y-BOCS reduction ≥ 25% (Simpson et al., 2006), in 18 patients was 67% (6 out of 9) with active and 22% (2 out of 9) with sham rTMS (Fig.”
BackgroundSelf-citationHawken, E., Dilkov, D., Kaludiev, E., Simek, S., Zhang, F., & Milev, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030420 · Cited by 94
“Clinical response rate, defined as Y-BOCS reduction of ě25% [35], was 80% (8 out of 10) in ACTIVE and 8% (1 out of 12) in SHAM.”
BackgroundEfficacy of cognitive-behavioral therapy for obsessive–compulsive disorder
McKay, D., Sookman, D., Neziroglu, F. A., Wilhelm, S., Stein, D. J., Kyrios, M., Matthews, K., & Veale, D. M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.02.004 · Cited by 111
“Simpson et al. (2006) reported that 37% (7 out of 19) of patients who received 3 months of Cognitive Behavior Therapy (CBT) plus Anafranil had recovered.”
Andersson, E., Steneby, S., Karlsson, K., Ljótsson, B., Hedman, E., Enander, J., Kaldo, V., Andersson, G., Lindefors, N., & Rück, C. (2014) · Psychological Medicine · doi:10.1017/s0033291714000543 · Cited by 88
“…for obsessive– compulsive disorder (OCD) has been investigated in clinical trials for more than 40 years (Rachman et al. 1971), and results have shown that this treatment is effective, in both group and individual format, with response rates averaging 50–70% (Abramowitz, 2006; Simpson et al. 2006).”
BackgroundObsessive compulsive disorder: diagnosis and management.
Fenske, J., & Schwenk, T. L. (2009) · PubMed · Cited by 109
Külz, A. K., Landmann, S., Cludius, B., Rose, N. L. J., Heidenreich, T., Jelinek, L., Alsleben, H., Wahl, K., Philipsen, A., Voderholzer, U., et al. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0957-4 · Cited by 107
Escitalopram prevents relapse of obsessive-compulsive disorder
Fineberg, N. A., Tonnoir, B., Lemming, O. M., & Stein, D. J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.11.005 · Cited by 95
“The analysis by Simpson et al. (2006) found that a Y-BOCS threshold score of 7 did not discriminate between active and control treatments, whereas a threshold score of 12 did.”
BackgroundDiMauro, J., Domingues, J., Fernandez, G., & Tolin, D. F. (2012) · Behaviour Research and Therapy · doi:10.1016/j.brat.2012.10.003 · Cited by 110
Wheaton, M. G., Galfalvy, H., Steinman, S. A., Wall, M. M., Foa, E. B., & Simpson, H. B. (2016) · Behaviour Research and Therapy · doi:10.1016/j.brat.2016.07.010 · Cited by 79
“Yet, not all patients achieve minimal symptoms at the end of treatment (e.g., 75–80% of patients respond, yet only 40–52% achieve remission; Farris et al. 2013; Simpson et al., 2006; Simpson et al., 2008; Simpson, Foa et al., 2013).”
BackgroundSelf-citationAn update on the efficacy of psychological treatments for obsessive-compulsive disorder in adults
Ponniah, K., Magiati, I., & Hollon, S. D. (2013) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2013.02.005 · Cited by 79
“…DIRT > ERP Vogel et al., 2004, 2006; Hansen et al., 2007 (NOR) DSM-III-R; ADIS; Mixed subtypes ERP plus CT or plus PMR > WL Foa et al., 2005; Simpson et al., 2004, 2005, 2006, 2008a DSM-III-R or DSM-IV; SCID ERP alone or plus meds > meds alone > pill placebo J Obsessive Compuls Relat Disord.”
BackgroundFear conditioning and extinction in obsessive-compulsive disorder: A systematic review
Cooper, S. E., & Dunsmoor, J. E. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.026 · Cited by 77
The therapeutic alliance in exposure therapy for anxiety-related disorders: A critical review
Buchholz, J. L., & Abramowitz, J. S. (2020) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2020.102194 · Cited by 77
Jaafari, N., Rachid, F., Rotge, J.-Y., Polosan, M., El-Hage, W., Belin, D., Vibert, N., & Pelissolo, A. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.575177 · Cited by 76
“…options which have improved the prognosis of OCD, 30 – 60% of patients are either unable to tolerate medication side effects or respond partially, thereby being left with persistent symptoms with lasting repercussions on their global functioning (Pallanti et al. 2002; Simpson et al. 2006).”
Refining clinical judgment of treatment outcome in obsessive–compulsive disorder
Lewin, A. B., Nadai, A. S. D., Park, J. M., Goodman, W. K., Murphy, T. K., & Storch, E. A. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.08.021 · Cited by 81
“Unfortunately, the OCD literature lacks a formal basis for determining optimal cut-off scores on assessment scales of clinical symptoms (Pallanti et al., 2002; Tolin et al., 2005; Simpson et al., 2006).”
BackgroundD’Urso, G., Brunoni, A. R., Anastasia, A., Micillo, M., de Bartolomeis, A., & Mantovani, A. (2016) · Neurocase · doi:10.1080/13554794.2015.1045522 · Cited by 72
Seo, H.-J., Jung, Y.-E., Lim, H. K., Um, Y.-H., Lee, C. U., & Chae, J.-H. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.2.153 · Cited by 70
da Silva, R. D. M. F., Brunoni, A. R., Goerigk, S. A., Batistuzzo, M. C., Costa, D. L. D. C., Diniz, J. B., Padberg, F., D’Urso, G., Miguel, E. C., & Shavitt, R. G. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00928-w · Cited by 82
Herbst, N., Voderholzer, U., Thiel, N., Schaub, R., Knaevelsrud, C., Stracke, S., Hertenstein, E., Nissen, C., & Külz, A. K. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357570 · Cited by 69
The Nordic long-term OCD treatment study (NordLOTS): rationale, design, and methods
Thomsen, P., Torp, N. C., Dahl, K., Christensen, K., Englyst, I., Melin, K. H., Nissen, J. B., Hybel, K. A., Valderhaug, R., Weidle, B., et al. (2013) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-7-41 · Cited by 68
“Those patients can be regarded to have mild OCD [51,52].”
Patel, S. R., Wheaton, M. G., Andersson, E., Rück, C., Schmidt, A. B., La Lima, C. N., Galfavy, H., Pascucci, O., Myers, R. W., Dixon, L. B., et al. (2018) · Behavior Therapy · doi:10.1016/j.beth.2017.09.003 · Cited by 67
“Finally, for the Y-BOCS, we used a ≥ 25% reduction in OCD symptoms as the definition for treatment response (Simpson et al., 2006).”
BackgroundMethodSelf-citationRoth, Y., Tendler, A., Arikan, M. K., Vidrine, R., Kent, D., Muir, O., MacMillan, C., Casuto, L., Grammer, G., Sauve, W., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.11.009 · Cited by 63
A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Self-citationVan Ameringen, M., Simpson, W., Patterson, B., Dell’Osso, B., Fineberg, N., Hollander, E., Hranov, L., Hranov, G., Lochner, C., Karamustafalioglu, O., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113517955 · Cited by 65
“Recent studies have shown that combination treatment is superior to SRI monotherapy but equivocal to CBT (with ERP) alone (Simpson et al., 2006).”
Poyurovsky, M., Glick, I., & Koran, L. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108099215 · Cited by 65
Predictors of Patient Adherence to Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder
Maher, M. J., Wang, Y., Zuckoff, A., Wall, M. M., Franklin, M., Foa, E. B., & Simpson, H. B. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000330214 · Cited by 65
Self-citationMaher, M. J., Huppert, J. D., Chen, H., Duan, N., Foa, E. B., Liebowitz, M. R., & Simpson, H. B. (2010) · Psychological Medicine · doi:10.1017/s0033291710000620 · Cited by 64
“However, 13–42% of patients have a partial response and 29–41% have a poor response to treatment (Simpson et al. 2006, 2008).”
BackgroundSelf-citationResidential treatment outcomes for adolescents with obsessive-compulsive disorder
Leonard, R. C., Franklin, M. E., Wetterneck, C. T., Riemann, B. C., Simpson, H. B., Kinnear, K., Cahill, S. P., & Lake, P. M. (2015) · Psychotherapy Research · doi:10.1080/10503307.2015.1065022 · Cited by 68
Self-citationCorrelates and mediators of functional disability in obsessive-compulsive disorder
Storch, E. A., Abramowitz, J. S., & Keeley, M. L. (2009) · Depression and Anxiety · doi:10.1002/da.20481 · Cited by 69
“There is a significant need for treatments to document real-world changes in addition to reductions in symptom severity([55,56]); assessing changes in disability is one manner of translating gains into realworld findings.”
BackgroundSimpson, H. B., Zuckoff, A., Page, J. R., Franklin, M. E., & Foa, E. B. (2008) · Cognitive Behaviour Therapy · doi:10.1080/16506070701743252 · Cited by 60
Self-citationShavitt, R. G., Valério, C., Fossaluza, V., da Silva, E. M., Cordeiro, Q., Diniz, J. B., Belotto-Silva, C., Cordioli, A. V., Mari, J. D. J., & Miguel, E. C. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0015-3 · Cited by 59
“The categorical criterion has been extensively adopted in the field and is considered conservative in respect to treatment response [30].”
Reid, A. M., Garner, L. E., Van Kirk, N., Gironda, C., Krompinger, J. W., Brennan, B. P., Mathes, B. M., Monaghan, S. C., Tifft, E. D., André, M.-C., et al. (2017) · Depression and Anxiety · doi:10.1002/da.22672 · Cited by 56
Treatment of Obsessive-Compulsive Disorder Complicated by Comorbid Eating Disorders
Simpson, H. B., Wetterneck, C. T., Cahill, S. P., STEINGLASS, J. E., Franklin, M. E., Leonard, R. C., Weltzin, T. E., & Riemann, B. C. (2013) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2012.751124 · Cited by 68
“To facilitate comparison with prior OCD clinical trials (Simpson et al., 2006), we also calculated the proportion of patients at discharge who met OCD response criteria (Y-BOCS-SR decrease $ 25”
MethodResultInfluentialSelf-citationRostami, R., Kazemi, R., Jabbari, A., Madani, A. S., Rostami, H., Taherpour, M. A., Molavi, P., Jaafari, N., Kuo, M.-F., Vicario, C. M., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02769-9 · Cited by 53
App-guided exposure and response prevention for obsessive compulsive disorder: an open pilot trial
Boisseau, C. L., Schwartzman, C. M., Lawton, J., & Mancebo, M. C. (2017) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2017.1321683 · Cited by 51
Sustained response versus relapse: the pharmacotherapeutic goal for obsessive–compulsive disorder
Fineberg, N. A., Pampaloni, I., Pallanti, S., Ipser, J., & Stein, D. J. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32825ea312 · Cited by 48
“Moreover, when Simpson et al. (2006) conducted a post-hoc analysis of previous trial data, application of different criteria for relapse led to different conclusions about efficacy.”
BackgroundMethodInfluentialCastro-Rodrigues, P., Camacho, M., Almeida, S., Marinho, M., Soares, C., Barahona-Corrêa, B., & Oliveira-Maia, A. J. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00431 · Cited by 63
O'Neill, J., & Feusner, J. (2015) · Psychology Research and Behavior Management · doi:10.2147/prbm.s75106 · Cited by 48
“Factors limiting access to CBT for OCD CBT, particularly intensive daily CBT,(1,2) is highly effective for OCD(3) with response rates of 50%–70%.(4,5) CBT offers comparable symptom improvement and lower relapse than time-limited pharmacotherapy.”
Palm, U., Leitner, B., Kirsch, B., Behler, N., Kumpf, U., Wulf, L., Padberg, F., & Hasan, A. (2017) · Neurocase · doi:10.1080/13554794.2017.1319492 · Cited by 53
Simpson, H. B., & Zuckoff, A. (2011) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2009.06.009 · Cited by 45
“As mentioned above, EX/RP is an efficacious treatment for some with OCD, but its effectiveness is limited in others by patient refusal, patient dropout, and partial adherence to the EX/RP procedures (Foa et al., 2005; Simpson et al., 2006).”
BackgroundSelf-citationMarazziti, D., Golia, F., Consoli, G., Presta, S., Pfanner, C., Carlini, M., Mungai, F., & Dell'Osso, M. C. (2008) · CNS Spectrums · doi:10.1017/s1092852900014024 · Cited by 45
Külz, A. K., Landmann, S., Cludius, B., Hottenrott, B., Rose, N., Heidenreich, T., Hertenstein, E., Voderholzer, U., & Moritz, S. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0314-8 · Cited by 41
“About thirty-five percent of the patients do not respond to the treatment recommended by current guidelines in terms of a reduction of symptom severity of at least 35% [11-13].”
BackgroundExposure therapy in a virtual environment: Validation in obsessive compulsive disorder
Cullen, A. J., Dowling, N. L., Segrave, R., Carter, A., & Yücel, M. (2021) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2021.102404 · Cited by 41
Storch, E. A., Lewin, A. B., Farrell, L., Aldea, M. A., Reid, J., Geffken, G. R., & Murphy, T. K. (2010) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2010.03.013 · Cited by 40
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap
Szechtman, H., Harvey, B. H., Woody, E. Z., & Hoffman, K. L. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017772 · Cited by 41
“This may explain in part why a significant portion of patients with OCD do not achieve relief and remission in clinical practice (Tolin et al., 2005; Simpson et al., 2006; Farris et al., 2013; Storch et al., 2015; Mataix-Cols et al., 2016).”
BackgroundTibi, L., van Oppen, P., van Balkom, A. J. L. M., Eikelenboom, M., Hendriks, G.-J., & Anholt, G. E. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.028 · Cited by 38
Nota, J. A., Schubert, J. R., & Coles, M. E. (2016) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2015.04.011 · Cited by 35
Obsessive–compulsive Disorder: Diagnostic and Treatment Issues
Stein, D. J., Denys, D. A. J. P., Gloster, A. T., Hollander, E., Leckman, J. F., Rauch, S. L., & Phillips, K. A. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.007 · Cited by 44
Simpson, H. B., Foa, E. B., Wheaton, M. G., Gallagher, T., Gershkovich, M., Schmidt, A. B., Huppert, J. D., Campeas, R. B., Imms, P., Cahill, S. P., et al. (2021) · Behaviour Research and Therapy · doi:10.1016/j.brat.2021.103890 · Cited by 41
Self-citationMantovani, A., Westin, G. G., Hirsch, J., & Lisanby, S. H. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.009 · Cited by 37
Kalanthroff, E., & Wheaton, M. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247379 · Cited by 35
“up to 20% who complete treatment do not experience a treatment response [27].”
BackgroundFoa, E. B., Simpson, H. B., Liebowitz, M. R., Powers, M. B., Rosenfield, D., Cahill, S. P., Campeas, R., Franklin, M., Hahn, C.-G., Hembree, E. A., et al. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08017 · Cited by 35
Self-citationSimpson, H. B., Foa, E. B., Liebowitz, M. R., Ledley, D. R., Huppert, J. D., Cahill, S., Vermes, D., Schmidt, A. B., Hembree, E., Franklin, M., et al. (2010) · Focus · doi:10.1176/foc.8.4.foc614 · Cited by 35
Self-citationda Silva, R. D. M. F., Brunoni, A. R., Miguel, E. C., & Shavitt, R. G. (2016) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2016.0155010716 · Cited by 39
Foa, E. B., Simpson, H. B., Rosenfield, D., Liebowitz, M. R., Cahill, S. P., Huppert, J. D., Bender Jr, J., McLean, C. P., Maher, M. J., Campeas, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09044 · Cited by 34
Self-citationArabzadeh, S., Shahhossenie, M., Mesgarpour, B., Rezaei, F., Shalbafan, M., Ghiasi, Z., & Akhondzadeh, S. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2584 · Cited by 39
Stepped care for obsessive-compulsive disorder: An open trial
Gilliam, C. M., Diefenbach, G. J., Whiting, S. E., & Tolin, D. F. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.07.010 · Cited by 31
Sookman, D., & Steketee, G. S. (2007) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2006.09.002 · Cited by 37
Wheaton, M. G., Huppert, J. D., Foa, E. B., & Simpson, H. B. (2016) · PubMed · Cited by 43
Self-citationTask-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder
Pagliaccio, D., Middleton, R., Hezel, D., Steinman, S., Snorrason, I., Gershkovich, M., Campeas, R., Pinto, A., Van Meter, P., Simpson, H. B., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909199116 · Cited by 30
Self-citationDavis, R. A., Giordano, J. J., Hufford, D. B., Sheth, S. A., Warnke, P. C., Widge, A. S., Richardson, R. M., Rosenow, J. M., Rossi, P. J., Storch, E. A., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.706181 · Cited by 33
“Even with optimal treatment, however, only about 35% of individuals with OCD achieve remission (defined as a YaleBrown Obsessive Compulsive Scale [Y-BOCS] score of ≤7) (23), and 10–20% remain severely affected (24).”
BackgroundSimpson, H. B., & Reddy, Y. C. J. (2014) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1229 · Cited by 32
Self-citationNakatani, E., Mataix‐Cols, D., Micali, N., Turner, C. M., & Heyman, I. (2008) · Child and Adolescent Mental Health · doi:10.1111/j.1475-3588.2008.00509.x · Cited by 33
The Nature, Assessment, and Treatment of Obsessive–Compulsive Disorder
McGuire, J. F., Lewin, A. B., Horng, B., Murphy, T. K., & Storch, E. A. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2528 · Cited by 28
Treatment Outcome and Predictors of Internet Guided Self-Help for Obsessive-Compulsive Disorder
Diefenbach, G. J., Wootton, B. M., Bragdon, L. B., Moshier, S. J., & Tolin, D. F. (2015) · Behavior Therapy · doi:10.1016/j.beth.2015.06.001 · Cited by 32
Long-term outcome following Intensive Residential Treatment of Obsessive–Compulsive Disorder
Stewart, S. E., Stack, D. E., Tsilker, S., Alosso, J., Stephansky, M. R., Hezel, D. M., Jenike, E. A., Haddad, S. A., Kant, J. D., & Jenike, M. A. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.03.012 · Cited by 28
“After reviewing the literature, Simpson et al. suggested a 25% YBOCS score decrease as a sensitive, but not necessarily specific measure of response (Simpson et al., 2006).”
MethodGershkovich, M., Middleton, R., Hezel, D. M., Grimaldi, S., Renna, M., Basaraba, C., Patel, S., & Simpson, H. B. (2021) · Behavior Therapy · doi:10.1016/j.beth.2020.05.001 · Cited by 25
Self-citationFoa, E. B., Simpson, H. B., Gallagher, T., Wheaton, M. G., Gershkovich, M., Schmidt, A. B., Huppert, J. D., Imms, P., Campeas, R. B., Cahill, S. P., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.3997 · Cited by 32
Self-citation
Metadata
- Authors
- Simpson, H. B., Huppert, J. D., Petkova, E., Foa, E. B., & Liebowitz, M. R.
- Affiliations
- New York State Psychiatric Institute (US)
- University of Pennsylvania (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-02-15
- Volume
- 67
- Issue
- 02
- Pages
- 269-276
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2011811397
- Cited by
- 241
- References
- 0
- Citations by year
- 2026: 13 · 2025: 11 · 2024: 8 · 2023: 7 · 2022: 14 · 2021: 21 · 2020: 8 · 2019: 17 · 2018: 12 · 2017: 12 · 2016: 13 · 2015: 15 · 2014: 11 · 2013: 15 · 2012: 15
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R01MH045404, R01MH-45404, K23MH001907, MH01907, R01MH045436, R01MH-45436)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- obsessive-compulsive disorder, treatment response, remission, exposure and response prevention, clomipramine, combination therapy, Yale-Brown Obsessive Compulsive Scale, comorbid depression, adults
- MeSH terms
- Adult, Ambulatory Care, Antidepressive Agents, Tricyclic, Clomipramine, Combined Modality Therapy, Female, Humans, Male, Terminology as Topic, Obsessive-Compulsive Disorder, Placebos, Psychiatric Status Rating Scales, Psychometrics, Cognitive Behavioral Therapy, Treatment Outcome, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.